5AM Ventures Closes $497M for Its Sixth Biotech Fund

글 내용 전체보기

Battered by a Tough Generics Market, Teva Pharma Emphasizes Biologics

글 내용 전체보기

In Going After Drug Prices, Congress Dredges up Some Old, Tired Issues

글 내용 전체보기

Merck Eyes Plans Phase III Programs in Prostate Cancer With Keytruda

글 내용 전체보기

BioSpace’s Global Biopharma Roundup: Feb. 14

글 내용 전체보기

Axovant Launches Arvelle Therapeutics to Commercialize Epilepsy Drug

글 내용 전체보기

Novartis’ Busy Day: 10-Target Deal With AbCellera and FDA Approves Parasite Drug

글 내용 전체보기

AstraZeneca Announces Pipeline Cuts, MedImmune Restructuring in 2018 Earnings

글 내용 전체보기

Staggering under load of talc litigation, J&J supplier Imerys America seeks shelter in bankruptcy

글 내용 전체보기

Merck aims for prostate cancer dominance with 3 new phase 3 Keytruda studies

글 내용 전체보기

Otsuka expects to shell out $120M to settle Avanir’s Nuedexta marketing probe

글 내용 전체보기

AstraZeneca rides high on sales rebound after cancer drugs, China once again pull through

글 내용 전체보기

Insys opioid reps rapped about boosting scripts by putting docs on the gravy train

글 내용 전체보기

EuroBiotech Report—AstraZeneca clear-out, uniQure data, Grey Wolf, Pathios and CureVac

글 내용 전체보기

EuroBiotech: More Articles of Note

글 내용 전체보기

Reprogramming pancreatic cells into insulin makers to treat diabetes

글 내용 전체보기

휴메딕스, 지난 4분기 매출 171억원…분기 최대 기록

글 내용 전체보기

Nimbus brings on Janssen discovery head as CSO with plans to expand its portfolio

글 내용 전체보기

제약사 1800억원 혈우병 시장놓고 ‘각축전’

글 내용 전체보기

Charles River CRO to continue to expand biomanufacturing support biz

글 내용 전체보기

안트로젠, 당뇨병성족부궤양 패치제 “2상서 효능확인”

글 내용 전체보기